In this assay, we evaluated the utility of @entity13302 given by a sprayer in the management of @entity101 crisis of @entity1468 . 36 pregnant @entity1 with @entity1468 received fluid therapy and were randomly dividend in two groups of 18 @entity1 each. Group A, received @entity13302 in spray 1.25 mg when admitted and a second dose 10 minutes after if mean arterial blood pressure decreased less than 15%. and group B, in whom 4 g of @entity2400 was infused in one hour and then 1 g each hour for a maximum of five hours. In all @entity1 blood pressure, @entity644 , fetal and maternal heart rate and Apgar score at minute and five minutes were obtained. In Group A 13 @entity1 had a significative blood pressure reduction with one application and 5 needed a second one (p < 0.002). fetal (p < 0.005), and maternal (p < 0.005) heart rate also had a significative reduction. Whereas three @entity1 in Group B did not respond and the rest had a poor blood pressure control (p > 0.05) with no changes in fetal and maternal heart rate. No @entity1 developed @entity3036 . When compared both groups, there were a significative difference for blood pressure (p < 0.005), fetal heart rate (p < 0.002), maternal heart rate (p < 0.05) and Apgar at minute (p < 0.01) in @entity13302 's group. Our data suggest that @entity13302 given by a sprayer is effective and safer in the management of the @entity101 crisis of @entity1468 .

[Efficacy of XXXX in aerosol form in the management of @entity101 crisis in @entity1468 ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity13302 :: ('MESH:D007547', 'Chemical') :: ['isosorbide'] @entity2400 :: ('CHEBI:32599', 'Chemical') :: ['magnesium sulphate'] @entity3036 :: ('MESH:D004461', 'Disease') :: ['eclampsia'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['severe preeclampsia']
@entity13302 :: (MESH:D007547,Chemical) :: ['isosorbide']
